Understanding patient-reported outcomes in disease states enhances our ability to provide patients with better care and an increased quality of life, said Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, director of outcomes research, WelldyneRx.
Understanding patient-reported outcomes in disease states enhances our ability to provide patients with better care and an increased quality of life, said Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, director of outcomes research, WelldyneRx.
Transcript
Are there certain disease states where patient-reported outcomes and real-world evidence are becoming more commonly used?
So, one of the first kind of disease categories where we’re seeing a lot of patient-reported outcomes being obtained in clinical practices, as well as from a managed care perspective, is in oncology patients. We want to see how patients are doing, as far as from their disease state, and are these drugs improving their quality of life, as well as helping with the disease. Other areas where patient-reported outcomes have a lot of potential and are currently being used is in the mental health space, in order to be able to identify when maybe there might need to be a change in therapy if there’s a correlation of a decrease in quality of life.
Also, MS [multiple sclerosis] is another area where we’re using a lot of quality of life outcomes. MS is a disease state that is very highly associated with disability, and by improving quality of life, that’s one of the main goals in treating patients with MS.
How are patient-reported outcomes being obtained?
So, obtaining patient-reported outcomes—there’s a wide spectrum of different types of patient-reported outcomes. There are validated surveys out there. There are some that are disease generic, and so you may use these patient-reported outcomes in different disease states. There are other patient-reported outcomes that are validated that are specific to a disease state. So, it depends on what practice works best in their workflow, or what will work best in the managed care or whatever setting you’re in, to be able to incorporate these different types of patient-reported outcomes to see how patients are responding to their therapy.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More